Discounted Cash Flow (DCF) Analysis Unlevered

Immix Biopharma, Inc. (IMMX)

$1.97

-0.07 (-3.43%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.97 | undervalue

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ---------
Revenue (%)
EBITDA ---------
EBITDA (%)
EBIT ---------
EBIT (%)
Depreciation ---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ---------
Total Cash (%)
Account Receivables ---------
Account Receivables (%)
Inventories ---------
Inventories (%)
Accounts Payable ---------
Accounts Payable (%)
Capital Expenditure ---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.97
Beta 0.000
Diluted Shares Outstanding 13.89
Cost of Debt
Tax Rate -0.12
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.784
Total Debt -
Total Equity 27.36
Total Capital 27.36
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ---------
EBITDA ---------
EBIT ---------
Tax Rate -2.16%-1.55%-0.02%-0.12%-0.97%-0.97%-0.97%-0.97%-0.97%
EBIAT ---------
Depreciation ---------
Accounts Receivable ---------
Inventories ---------
Accounts Payable ---------
Capital Expenditure -0.01--0------
UFCF ---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.78
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -13.44
Equity Value -
Shares Outstanding 13.89
Equity Value Per Share -